Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05237986 · ClinicalTrials.gov registry record

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

A clinical trial of Lymphoma and Leukemia, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
60
Enrollment target
3
Study locations

NCT05237986 is a study of Lymphoma and Leukemia that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05237986, a study of Lymphoma and Leukemia, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
60 participants
Enrollment target
3
Study locations

Study Summary

Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically interested in learning if and how this treatment may affect the brain or your thinking skills. Objective: To learn if CAR T-cell therapy can affect how children and adults think, process, and remember things. Eligibility: People aged 5-35 who have blood cancer that has not responded to treatment, or the blood cancer has come back after treatment, and who will receive CAR T-cell therapy. Caregivers are also needed. All participants must be able to speak and read in English or Spanish. Design: Participants will be screened with a medical history. Information from participants medical records will be collected. Participants will take tests at home or at NIH to see how well they think, read, learn, remember, reason, and pay attention. The tests will be both computerized and paper/pencil. They will take less than 1 hour to complete. Participants and a parent/adult observer will complete a 5-minute Background Information Form and a checklist of nervous system symptoms. If participants are 5 years or older, they will participate in activities to test their ability to do different thinking tasks, like answer questions, complete puzzle patterns, and remember things. Participants and their caregivers will complete questions to see if they are having specific symptoms related to receiving CAR T-cells. The questions will assess their well-being and needs. The questions will take less than 1 hour to complete. Some tests and questions will be repeated at different time points in the study. Participation will last for up to 3 years.

Conditions Studied

Study Locations (3)

California

  • Children s Hospital of Los Angeles - Los Angeles

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Washington

  • Seattle Children s Hospital - Seattle

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-06-23
Est. Completion 2027-04-30

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT05237986

The ClinicalTrials.gov registry entry for NCT05237986 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (88% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphoma appearing as the primary indexed condition, and to 0 interventions.

NCT05237986 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Maryland, Washington.

Frequently Asked Questions

What is clinical trial NCT05237986 about?

NCT05237986 is a clinical study titled "Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy". Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Researchers want to learn more about the effects of potential problems that may be associated with this treatment. We are specifically in...

What is the current status of trial NCT05237986?

This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2025-06-23. Estimated completion is 2027-04-30.

What conditions does trial NCT05237986 study?

This clinical trial studies the following conditions: Lymphoma, Leukemia.

Who is sponsoring clinical trial NCT05237986?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05237986 being conducted?

This trial has 3 study locations across California, Maryland, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.